New immunotherapy cocktail aims to outsmart kidney cancer

NCT ID NCT07000149

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This large global trial is testing whether two experimental drugs—volrustomig (an immunotherapy) and casdatifan (a pill)—work better than the current standard immunotherapy combination for people with advanced clear cell kidney cancer. About 1,100 participants who have not had prior treatment will be randomly assigned to one of the new combinations or the standard therapy. The study will measure how long people live without their cancer worsening and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Volrustomig (an immunotherapy drug) and Casdatifan (a pill that targets cancer cells)
What this could lead to: If successful, this could offer a new first-line treatment option for advanced kidney cancer that may be more effective than current standard therapy.
What could go wrong: This is an early-stage combination test; it may not prove better than existing treatments, and side effects from the new drugs could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma kidney cancer renal cell carcinoma type 1 diabetes mellitus 12

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CLEAR CELL RENAL CELL CARCINOMA

Contacts and locations

Locations

Research Site

Elizabeth Vale, 5112, Australia
Research Site

Busan, 48108, South Korea
Research Site

Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.